Edwards Lifesciences CorporationEWNYSE
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank23
Year-over-Year Change
Year-over-year free cash flow growth rate
Percentile
P23
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -31.52% |
| Q3 2025 | 114.28% |
| Q2 2025 | 7.35% |
| Q1 2025 | 226.57% |
| Q4 2024 | -155.42% |
| Q3 2024 | 11.81% |
| Q2 2024 | 306.12% |
| Q1 2024 | -496.57% |
| Q4 2023 | -90.17% |
| Q3 2023 | 2590.91% |
| Q2 2023 | -105.66% |
| Q1 2023 | 30.41% |
| Q4 2022 | -22.52% |
| Q3 2022 | -13.52% |
| Q2 2022 | 31.05% |
| Q1 2022 | -21.16% |
| Q4 2021 | -40.62% |
| Q3 2021 | 3.15% |
| Q2 2021 | 134.86% |
| Q1 2021 | -32.11% |
| Q4 2020 | 153.99% |
| Q3 2020 | -8.22% |
| Q2 2020 | -1.52% |
| Q1 2020 | -61.94% |
| Q4 2019 | -9.22% |
| Q3 2019 | 34.08% |
| Q2 2019 | 568.52% |
| Q1 2019 | -124.74% |
| Q4 2018 | -10.68% |
| Q3 2018 | 197.71% |
| Q2 2018 | -16.84% |
| Q1 2018 | -66.31% |
| Q4 2017 | 16.64% |
| Q3 2017 | 96.69% |
| Q2 2017 | 23.97% |
| Q1 2017 | -20.45% |
| Q4 2016 | -12.50% |
| Q3 2016 | 40.59% |
| Q2 2016 | 41.18% |
| Q1 2016 | 27.04% |